This article is more than 5 years old. Information may no longer be current.
Vical to stop development of Allovectin as melanoma treatment
Click Here to Manage Email Alerts
Vical Inc. announced today that it is stopping the development of its investigational cancer drug for treating patients with metastatic melanoma following results of a phase 3 trial.
The study of 390 patients failed to demonstrate a statistically significant improvement between velimogene aliplasmid (Allovectin), an intratumoral cancer immunotherapy, and first-line chemotherapy in objective response rate at 24 weeks or more after randomization (primary endpoint) or overall survival (secondary endpoint), according to a press release.
“We are disappointed that the trial did not meet either the primary or secondary efficacy endpoints,” Vijay B. Samant, president and chief executive officer of Vical said in the release. “Based on this outcome, we are terminating the Allovectin program and focusing our resources on our infectious disease vaccine programs.”
Velimogene aliplasmid study results will be further analyzed and submitted for publication, according to the release.